MX2023013062A - Monoterapia con inhibidores de shp2 y usos de la misma. - Google Patents
Monoterapia con inhibidores de shp2 y usos de la misma.Info
- Publication number
- MX2023013062A MX2023013062A MX2023013062A MX2023013062A MX2023013062A MX 2023013062 A MX2023013062 A MX 2023013062A MX 2023013062 A MX2023013062 A MX 2023013062A MX 2023013062 A MX2023013062 A MX 2023013062A MX 2023013062 A MX2023013062 A MX 2023013062A
- Authority
- MX
- Mexico
- Prior art keywords
- recommended
- generate
- contact
- tactic
- orchestration
- Prior art date
Links
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 title abstract 3
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 238000009097 single-agent therapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184710P | 2021-05-05 | 2021-05-05 | |
| US202263320991P | 2022-03-17 | 2022-03-17 | |
| PCT/US2022/027703 WO2022235822A1 (en) | 2021-05-05 | 2022-05-04 | Shp2 inhibitor monotherapy and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013062A true MX2023013062A (es) | 2023-11-15 |
Family
ID=83932911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013062A MX2023013062A (es) | 2021-05-05 | 2022-05-04 | Monoterapia con inhibidores de shp2 y usos de la misma. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12390469B2 (enExample) |
| EP (1) | EP4333850A4 (enExample) |
| JP (1) | JP2024516997A (enExample) |
| AU (1) | AU2022271244A1 (enExample) |
| CA (1) | CA3217097A1 (enExample) |
| IL (1) | IL308234A (enExample) |
| MX (1) | MX2023013062A (enExample) |
| WO (1) | WO2022235822A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022235822A1 (en) | 2021-05-05 | 2022-11-10 | Huabio International, Llc | Shp2 inhibitor monotherapy and uses thereof |
| MX2023012929A (es) * | 2021-05-05 | 2023-11-13 | Huyabio Int Llc | Terapias de combinacion que comprenden inhibidores de shp2 e inhibidores de tirosina cinasa egfr. |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| EP4536364A1 (en) | 2022-06-10 | 2025-04-16 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN121013721A (zh) * | 2022-11-23 | 2025-11-25 | 沪亚生物国际有限公司 | 包含kras抑制剂和sph2抑制剂的组合疗法 |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| CN121487951A (zh) | 2023-04-07 | 2026-02-06 | 锐新医药公司 | 大环ras抑制剂 |
| EP4695261A1 (en) | 2023-04-14 | 2026-02-18 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| AU2024251341A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| WO2016203406A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| WO2017210134A1 (en) | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Heterocyclic inhibitors of ptpn11 |
| KR102218333B1 (ko) | 2016-06-07 | 2021-02-22 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| PT3468972T (pt) | 2016-06-14 | 2020-08-21 | Novartis Ag | Compostos e composições para inibir a atividade da shp2 |
| IL311645B2 (en) | 2016-07-12 | 2025-11-01 | Revolution Medicines Inc | 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors |
| CN110730678B (zh) | 2017-01-10 | 2022-07-15 | 诺华股份有限公司 | 包含alk抑制剂和shp2抑制剂的药物组合 |
| SG11201908820VA (en) | 2017-03-23 | 2019-10-30 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
| TWI852912B (zh) | 2017-09-07 | 2024-08-21 | 美商銳新醫藥公司 | Shp2抑制劑組合物以及治療癌症的方法 |
| BR112020007058A2 (pt) | 2017-10-12 | 2020-10-06 | Revolution Medicines, Inc. | compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos |
| WO2019126736A1 (en) | 2017-12-21 | 2019-06-27 | New York University | Pd-1 related cancer therapy |
| WO2019152454A1 (en) | 2018-01-30 | 2019-08-08 | Research Development Foundation | Shp2 inhibitors and methods of use thereof |
| RU2020133727A (ru) | 2018-03-21 | 2022-04-21 | Сучжоу Пухе Биофарма Ко., Лтд. | Ингибиторы shp2 и их применение |
| KR20200143417A (ko) | 2018-04-10 | 2020-12-23 | 레볼루션 메디슨즈, 인크. | Shp2 억제제 조성물, 암을 치료하는 방법 및 shp2 돌연변이를 갖는 대상체를 확인하는 방법 |
| EP3923940B1 (en) | 2019-02-12 | 2025-12-03 | Novartis AG | Pharmaceutical combination comprising tno155 and a pd-1 inhibitor |
| US12343344B2 (en) * | 2019-02-12 | 2025-07-01 | Novartis Ag | Pharmaceutical combination comprising TNO155 and ribociclib |
| CN111647000B (zh) * | 2019-03-04 | 2021-10-12 | 勤浩医药（苏州）有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
| CN114502165A (zh) * | 2019-09-23 | 2022-05-13 | 苏州浦合医药科技有限公司 | Shp2抑制剂及其用途 |
| WO2022235822A1 (en) | 2021-05-05 | 2022-11-10 | Huabio International, Llc | Shp2 inhibitor monotherapy and uses thereof |
-
2022
- 2022-05-04 WO PCT/US2022/027703 patent/WO2022235822A1/en not_active Ceased
- 2022-05-04 EP EP22799524.8A patent/EP4333850A4/en not_active Withdrawn
- 2022-05-04 MX MX2023013062A patent/MX2023013062A/es unknown
- 2022-05-04 CA CA3217097A patent/CA3217097A1/en active Pending
- 2022-05-04 AU AU2022271244A patent/AU2022271244A1/en active Pending
- 2022-05-04 US US17/736,908 patent/US12390469B2/en active Active
- 2022-05-04 IL IL308234A patent/IL308234A/en unknown
- 2022-05-04 JP JP2023567922A patent/JP2024516997A/ja active Pending
-
2025
- 2025-08-15 US US19/301,569 patent/US20250367204A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12390469B2 (en) | 2025-08-19 |
| WO2022235822A1 (en) | 2022-11-10 |
| US20250367204A1 (en) | 2025-12-04 |
| JP2024516997A (ja) | 2024-04-18 |
| EP4333850A4 (en) | 2025-04-09 |
| AU2022271244A1 (en) | 2023-12-07 |
| US20220370458A1 (en) | 2022-11-24 |
| IL308234A (en) | 2024-01-01 |
| EP4333850A1 (en) | 2024-03-13 |
| CA3217097A1 (en) | 2022-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021500005A1 (en) | Sulfonimidamide compounds as inhibitors of interleukin-1 activity | |
| EP4579519A3 (en) | Natural assistant interaction | |
| PH12019501623A1 (en) | Blockchain-based data processing method and device | |
| ATE557355T1 (de) | Eingriffs-verarbeitung | |
| WO2020191041A3 (en) | Biomarkers for vitiligo | |
| MX2025004193A (es) | Inhibidores del inhibidor 1 de activador de plasminogeno (pai-1) y usos de los mismos | |
| MX388395B (es) | Guardado y restauracion de estado de maquina entre multiples ejecuciones de una instruccion | |
| WO2019204332A3 (en) | Pak4 inhibitors and methods of use | |
| MX2026001352A (es) | Tratamiento de cancer de prostata | |
| NZ603548A (en) | Use of aromatase inhibitors for synchronizing ovulation, inducing superovulation or double ovulation and improving twinning and fertility in a mammal | |
| WO2020123835A9 (en) | Acoustic echo cancellation during playback of encoded audio | |
| WO2021211921A3 (en) | Methods of reducing or preventing clostridioides difficile colonization | |
| MX2024005539A (es) | Concepto de generacion de patrones de reflexiones tempranas para auralizacion. | |
| WO2023153083A9 (ja) | 情報処理装置、情報処理方法、情報処理プログラム及び移動装置 | |
| FR2867401B1 (fr) | Planeuse a entraxe variable | |
| ZA202403482B (en) | Early reflection concept for auralization | |
| MX2021004818A (es) | Metodo de enchapado por inmersion en caliente. | |
| WO2024254180A3 (en) | Compositions and methods to mitigate phytotoxic effects of agrichemicals | |
| SA519410082B1 (ar) | طلاء أنابيب الكربون الصلب بكبريتيد الحديد | |
| Whitten et al. | Radar properties of the Dorsa Argentea Formation, Mars determined from SHARAD and MARSIS data | |
| MX358649B (es) | Proceso de evaluacion y seleccion para productos de consumo. | |
| MX2023015288A (es) | Terapia combinada con inhibidores de erk1/2 y egfr. | |
| Liu | Research on Practice Teaching of Chain Enterprise Financial Management in Advanced Vocational Technical College | |
| Li et al. | Cross-correlation reflection waveform inversion based on the time-shift weighted norm calculated by the dynamic image warping | |
| Chen et al. | An Empirical Analysis on the Relationship between Corporate Social Responsibility and Enterprise Competitiveness |